136 related articles for article (PubMed ID: 36753835)
1. Identification of high-risk patients with a seven-biomarker prognostic signature for adjuvant treatment trial recruitment in American Joint Committee on Cancer v8 stage I-IIA cutaneous melanoma.
Meyer S; Buser L; Haferkamp S; Berneburg M; Maisch T; Klinkhammer-Schalke M; Pauer A; Vogt T; Garbe C
Eur J Cancer; 2023 Mar; 182():77-86. PubMed ID: 36753835
[TBL] [Abstract][Full Text] [Related]
2. Epidermal autophagy and beclin 1 regulator 1 and loricrin: a paradigm shift in the prognostication and stratification of the American Joint Committee on Cancer stage I melanomas.
Ellis R; Tang D; Nasr B; Greenwood A; McConnell A; Anagnostou ME; Elias M; Verykiou S; Bajwa D; Ewen T; Reynolds NJ; Barrett P; Carling E; Watson G; Armstrong J; Allen AJ; Horswell S; Labus M; Lovat PE
Br J Dermatol; 2020 Jan; 182(1):156-165. PubMed ID: 31056744
[TBL] [Abstract][Full Text] [Related]
3. Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma.
Amaral TMS; Hoffmann MC; Sinnberg T; Niessner H; Sülberg H; Eigentler TK; Garbe C
Eur J Cancer; 2020 Jan; 125():38-45. PubMed ID: 31838403
[TBL] [Abstract][Full Text] [Related]
4. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification.
Ferris LK; Farberg AS; Middlebrook B; Johnson CE; Lassen N; Oelschlager KM; Maetzold DJ; Cook RW; Rigel DS; Gerami P
J Am Acad Dermatol; 2017 May; 76(5):818-825.e3. PubMed ID: 28110997
[TBL] [Abstract][Full Text] [Related]
5. Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma.
Kanaki T; Stang A; Gutzmer R; Zimmer L; Chorti E; Sucker A; Ugurel S; Hadaschik E; Gräger NS; Satzger I; Schadendorf D; Livingstone E
Eur J Cancer; 2019 Sep; 119():18-29. PubMed ID: 31401470
[TBL] [Abstract][Full Text] [Related]
6. External validation of the American Joint Committee on Cancer melanoma staging system eighth edition using the surveillance, epidemiology, and end results program.
Tjokrowidjaja A; Browne L; Soudy H
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e280-e288. PubMed ID: 34811927
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma.
Hsueh EC; DeBloom JR; Lee JH; Sussman JJ; Covington KR; Caruso HG; Quick AP; Cook RW; Slingluff CL; McMasters KM
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036233
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
[TBL] [Abstract][Full Text] [Related]
9. Improved cutaneous melanoma survival stratification through integration of 31-gene expression profile testing with the American Joint Committee on Cancer 8th Edition Staging.
Wisco OJ; Marson JW; Litchman GH; Brownstone N; Covington KR; Martin BJ; Quick AP; Siegel JJ; Caruso HG; Cook RW; Winkelmann RR; Rigel DS
Melanoma Res; 2022 Apr; 32(2):98-102. PubMed ID: 35254332
[TBL] [Abstract][Full Text] [Related]
10. Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors.
Waninger JJ; Ma VT; Journey S; Skvarce J; Chopra Z; Tezel A; Bryant AK; Mayo C; Sun Y; Sankar K; Ramnath N; Lao C; Sussman JB; Fecher L; Alva A; Green MD
JAMA Netw Open; 2021 Mar; 4(3):e210980. PubMed ID: 33687443
[TBL] [Abstract][Full Text] [Related]
11. Identification and validation of an epithelial mesenchymal transition-related gene pairs signature for prediction of overall survival in patients with skin cutaneous melanoma.
Shi Y; Li Z; Zhou Z; Liao S; Wu Z; Li J; Yin J; Wang M; Weng M
PeerJ; 2022; 10():e12646. PubMed ID: 35116193
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of microsatellites in melanoma and implications in the American Joint Committee on Cancer classification system: A cohort study.
Riquelme-Mc Loughlin C; Sandoval-Clavijo A; Blanco de Tord M; Boada A; Alos L; García A; Carrera C; Malvehy J; Puig S; Toll A; Podlipnik S
J Am Acad Dermatol; 2023 Feb; 88(2):338-347. PubMed ID: 36265824
[TBL] [Abstract][Full Text] [Related]
13. Differences in cutaneous melanoma survival between the 7th and 8th edition of the American Joint Committee on Cancer (AJCC). A multicentric population-based study.
Barreiro-Capurro A; Andrés-Lencina JJ; Podlipnik S; Carrera C; Requena C; Manrique-Silva E; Quaglino P; Tonella L; Jaka A; Richarz N; Rodríguez-Peralto JL; Ortiz P; Boada A; Ribero S; Nagore E; Malvehy J; Puig S
Eur J Cancer; 2021 Mar; 145():29-37. PubMed ID: 33418234
[TBL] [Abstract][Full Text] [Related]
14. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
Gershenwald JE; Scolyer RA; Hess KR; Sondak VK; Long GV; Ross MI; Lazar AJ; Faries MB; Kirkwood JM; McArthur GA; Haydu LE; Eggermont AMM; Flaherty KT; Balch CM; Thompson JF;
CA Cancer J Clin; 2017 Nov; 67(6):472-492. PubMed ID: 29028110
[TBL] [Abstract][Full Text] [Related]
15. Melanoma long non-coding RNA signature predicts prognostic survival and directs clinical risk-specific treatments.
Chen X; Guo W; Xu XJ; Su F; Wang Y; Zhang Y; Wang Q; Zhu L
J Dermatol Sci; 2017 Mar; 85(3):226-234. PubMed ID: 27955882
[TBL] [Abstract][Full Text] [Related]
16. High MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malignant melanoma.
Nodin B; Fridberg M; Jonsson L; Bergman J; Uhlén M; Jirström K
Diagn Pathol; 2012 Jul; 7():82. PubMed ID: 22805320
[TBL] [Abstract][Full Text] [Related]
17. A population-based validation of the American Joint Committee on Cancer melanoma staging system.
Gimotty PA; Botbyl J; Soong SJ; Guerry D
J Clin Oncol; 2005 Nov; 23(31):8065-75. PubMed ID: 16258105
[TBL] [Abstract][Full Text] [Related]
18. Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease.
Moncrieff MD; Lo SN; Scolyer RA; Heaton MJ; Nobes JP; Snelling AP; Carr MJ; Nessim C; Wade R; Peach AH; Kisyova R; Mason J; Wilson ED; Nolan G; Pritchard Jones R; Johansson I; Olofsson Bagge R; Wright LJ; Patel NG; Sondak VK; Thompson JF; Zager JS
J Clin Oncol; 2022 Dec; 40(34):3940-3951. PubMed ID: 35849790
[TBL] [Abstract][Full Text] [Related]
19. A Prognostic Gene Signature Expressed in Primary Cutaneous Melanoma: Synergism With Conventional Staging.
Brunner G; Heinecke A; Falk TM; Ertas B; Blödorn-Schlicht N; Schulze HJ; Suter L; Atzpodien J; Berking C
JNCI Cancer Spectr; 2018 Jul; 2(3):pky032. PubMed ID: 31360859
[TBL] [Abstract][Full Text] [Related]
20. Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma.
Hoshimoto S; Faries MB; Morton DL; Shingai T; Kuo C; Wang HJ; Elashoff R; Mozzillo N; Kelley MC; Thompson JF; Lee JE; Hoon DS
Ann Surg; 2012 Feb; 255(2):357-62. PubMed ID: 22202581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
